POS1046 IMPROVEMENTS IN PATIENT-REPORTED IMPACT OF PSORIATIC ARTHRITIS WITH IL-12/23 (USTEKINUMAB) OR TUMOUR NECROSIS FACTOR INHIBITORS: 1-YEAR DATA FROM THE LARGE, REAL-WORLD PsABIO STUDY
Authors: L. Gossec, S. Siebert, P. Bergmans, K. De Vlam, E. Gremese, B. Joven-Ibáñez, T. Korotaeva, W. Noel, M. Nurmohamed, P. Sfikakis, E. Theander, J. S. Smolen
Journal: Annals of the Rheumatic Diseases (2021)

Background: Psoriatic arthritis (PsA) negatively impacts patients’ (pts) quality of life (QoL), with a high burden of pain, fatigue and psychological distress. The 12-item Psoriatic Arthritis Impact of Disease questionnaire (PsAID-12) is a validated measure of pt-reported disease impact. Objectives: To analyse PsAID-12 score changes in the overall population and specific subgroups of interest, and assess correlation of these changes using Health Assessment Questionnaire Disability Index (HAQ-DI). Methods: PsABio ( NCT02627768 ) is a multinational, prospective, observational study in pts with PsA receiving ustekinumab (UST) or a tumour necrosis factor inhibitor (TNFi) as a 1st/2nd/3rd-line biologic. Descriptive statistics, including 95% CI, are presented at baseline (BL) and 1 year. Linear regression, including propensity score (PS) adjustment for BL covariates, was used to compare change in PsAID-12 total from BL to 1 year between treatments. The relationship between changes in PsAID-12 and HAQ-DI was investigated using Spearman’s correlation. Results: Data were available for 438 UST and 455 TNFi pts. From BL to 1 year, significant improvements were seen in total PsAID-12 scores and in all domains with both treatments (Figure 1). PS-adjusted treatment comparison showed no difference in total PsAID-12 improvement (regression coefficient [95% CI]: 0.14 [-0.22; 0.51], p=0.4433), or in any domain, except skin problems, which improved significantly more with UST than TNFi (-0.55 [-1.04, -0.06], p=0.0277). Improvements in PsAID-12 and HAQ-DI showed strong positive correlation with both treatments (UST: r=0.63, p&lt;0.0001; TNFi: r=0.70, p&lt;0.0001). Effectiveness was demonstrated with UST and TNFi in subgroups of interest, including biologic treatment line, sex and psoriasis extent (Table 1. next page). Conclusion: Treatment with IL-12/23 (UST) or TNF inhibitors significantly improved pt-reported disease impact at 1 year. PS-adjusted PsAID-12 improvements did not differ significantly between treatments, except skin problems (better with UST). Improvements in disease impact and physical functioning (HAQ-DI) were strongly correlated, emphasising the effect of these biologics on QoL in PsA pts. Figure 1. Table 1. PsAID-12 scores by BL characteristic subgroup Mean (95% CI ) UST TNFi BL Unadjusted change from BL at 1 year (LOCF ) BL Unadjusted change from BL at 1 year (LOCF ) Biologic line 1st 5.51 (5.19; 5.82) -2.14 (-2.49; -1.79) 5.44 (5.15; 5.72) -2.41 (-2.72; -2.09) 2nd 6.05 (5.69; 6.41) -2.14 (-2.55; -1.72) 5.57 (5.19; 5.95) -2.37 (-2.79; -1.94) 3rd 5.84 (5.33; 6.35) -1.81 (-2.45; -1.17) 5.34 (4.52; 6.15) -1.89 (-2.62; -1.16) Sex* Male 5.27 (4.95; 5.59) -2.35 (-2.70; -1.99) 4.89 (4.56; 5.23) -2.49 (-2.83; -2.15) Female 6.14 (5.86; 6.43) -1.86 (-2.20; -1.52) 5.95 (5.67; 6.23) -2.20 (-2.53; -1.87) Enthesitis Yes 5.95 (5.66; 6.24) -2.19 (-2.51; -1.86) 5.89 (5.61; 6.17) -2.65 (-2.98; -2.31) No 5.51 (5.19; 5.83) -1.98 (-2.36; -1.59) 4.99 (4.65; 5.32) -2.02 (-2.35; -1.68) Psoriasis BSA, % &lt;3 5.66 (5.32; 6.00) -1.60 (-2.03; -1.18) 4.97 (4.63; 5.31) -1.89 (-2.25; -1.52) 3–10 5.44 (5.05; 5.83) -2.16 (-2.59; -1.74) 5.78 (5.43; 6.14) -2.99 (-3.38; -2.59) &gt;10 6.15 (5.70; 6.60) -2.93 (-3.43; -2.43) 6.13 (5.55; 6.71) -2.86 (-3.49; -2.23) Joint involvement † Mono/oligoarticular 5.07 (4.56; 5.58) -1.96 (-2.47; -1.45) 4.82 (4.38; 5.25) -2.18 (-2.66; -1.70) Polyarticular 5.98 (5.75; 6.22) -2.21 (-2.51; -1.92) 5.78 (5.52; 6.04) -2.47 (-2.75; -2.18) FiRST score* &lt;5 5.15 (4.87; 5.44) -2.18 (-2.50; -1.87) 5.10 (4.83; 5.36) -2.44 (-2.71; -2.16) ≥5 6.72 (6.43; 7.00) -1.95 (-2.38; -1.53) 6.49 (6.15; 6.83) -2.09 (-2.57; -1.61) *At BL, female pts and pts with FiRST score ≥5 (chronic widespread pain) were significantly more impacted than male pts and pts with FiRST score &lt;5, and remained significantly more impacted at 1 year. † Polyarticular pts were significantly more impacted at BL, but not 1 year. BSA, body surface area; CI, confidence interval; FiRST, Fibromyalgia Rapid Screening Tool; LOCF, last observation carried forward Acknowledgements: This study was funded by Janssen. Disclosure of Interests: Laure Gossec Consultant of: AbbVie, Amgen, Bioepis, Biogen, Bristol-Myers Squibb, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung, Sanofi-Aventis, UCB, Grant/research support from: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi, Stefan Siebert Speakers bureau: AbbVie, Amgen (previously Celgene), Biogen, Janssen, Novartis, UCB, Consultant of: AbbVie, Janssen, UCB, Grant/research support from: Amgen (previously Celgene), Boehringer Ingelheim, Bristol-Myers Squibb, GSK, Janssen, Novartis, Pfizer, UCB, Paul Bergmans Shareholder of: Johnson &amp; Johnson, Employee of: Janssen, Kurt de Vlam Speakers bureau: AbbVie, Amgen, Eli Lilly, Novartis, UCB, Paid instructor for: Amgen, Galapagos, UCB, Consultant of: Eli Lilly, Galapagos, Johnson &amp; Johnson, Novartis, UCB, Grant/research support from: Celgene, Elisa Gremese: None declared, Beatriz Joven-Ibáñez Speakers bureau: AbbVie, Celgene, Janssen, MSD, Novartis, Pfizer, Tatiana Korotaeva Speakers bureau: AbbVie, Amgen, Biocad, Lilly, Janssen, MSD, Novartis, Novartis-Pfizer, Sandoz, UCB, Consultant of: AbbVie, Amgen, Biocad, Lilly, Janssen, MSD, Novartis, Novartis-Sandoz, Pfizer, UCB, Grant/research support from: Pfizer, Wim Noel Employee of: Janssen, Michael Nurmohamed Speakers bureau: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi, UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi, UCB, Grant/research support from: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Menarini, MSD, Mundipharma, Pfizer, Roche, Sanofi, UCB, Petros Sfikakis Consultant of: AbbVie, Actelion, Boehringer Ingelheim, Enorasis, Farmaserv-Lilly, Genesis, Gilead, Pfizer, MSD, Novartis, UCB, Grant/research support from: AbbVie, Amgen, Boehringer Ingelheim, Faran, Janssen, Pfizer, Roche, Elke Theander Employee of: Janssen, Josef S. Smolen Speakers bureau: AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, ILTOO, Janssen, Lilly, MSD, Novartis- Sandoz, Pfizer, Roche, Samsung, Sanofi, UCB, Grant/research support from: AbbVie, AstraZeneca, Lilly, Novartis, Roche.